Aaron Gerds, MD, MS, explores myelofibrosis risk assessment, treatment goals, and therapeutic strategies, including JAK (Janus kinase inhibitors) inhibitors and transplant considerations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback